Tagraxofusp
Tagraxofusp-erzs (trade name Elzonris) is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.[1]
| Clinical data | |
|---|---|
| Trade names | Elzonris |
| Other names | DT388-IL3; SL-401 |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Proteases (expected) |
| Elimination half-life | 51 minutes |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2553H4026N692O798S16 |
| Molar mass | 57695.30 g·mol−1 |
Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.[2] The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2).
References
- "FDA approves first treatment for rare blood disease" (Press release). Food and Drug Administration. December 21, 2018.
- "ELZONRIS (tagraxofusp, SL-401)". Stemline Therapeutics.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.